Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with Type 2 diabetes and cardiovascular disease
Mostafa SA, Coleman RL, Agbaje OF, et al.
Diabet Med 2018;35(1):72-7
Leggi
Breaking news
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
Garg SK, Henry RR, Banks P, et al.
N Engl J Med 2017;377:2337-48
Leggi
FDA approves Admelog, the first short-acting “follow-on” insulin product to treat diabetes
14/12/2017
Leggi
Prevalence and severity of non-alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital
Marjot T, Sbardella E, Moolla A, et al.
Diabet Med. Pub. online 10 December 2017
Leggi
American Diabetes Association. Standards of Medical Care in Diabetes 2018
American Diabetes Association
Diabetes Care. 2018;41(1)
Leggi
FDA approves Admelog, the first short-acting “follow-on” insulin product to treat diabetes
11/12/2017
Leggi
Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)
Zinman B, Marso SP, Poulter NR et al.
Diabetologia 2018 61(1):48-57
Leggi
Spectrum of mutations in monogenic diabetes genes identified from high-throughput DNA sequencing of 6888 individuals
Bansal V, Gassenhuber J, Phillips T, et al.
BMC Medicine. Pub. online 6 December 2017
Leggi
How Pure is PURE? Dietary Lessons Learned and Not Learned From the PURE Trials
Gianos E, Williams KA, Freeman AM, et al.
Am J Med. Pub. online 8 December 2017
Leggi
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
Bethel MA
Lancet Diabetes Endocrinol. Pub. online 5 December 2017
Leggi